Abbott launches blood sugar sensor for non-diabetics in October 2023

Abbott has launched its new continuous glucose monitors (CGMs) for over-the-counter use, targeting individuals without diabetes who wish to monitor their blood sugar levels. These devices, including Abbott's Lingo, are designed to help users understand how various factors such as diet, exercise, and stress affect their glucose levels. The FDA has cleared these monitors for adults seeking insights into their metabolic health, which is increasingly recognized as a critical aspect of overall well-being. The introduction of these consumer-friendly CGMs follows a similar move by Dexcom, another key player in diabetes technology. Both companies aim to capitalize on the growing interest in personal health monitoring, particularly among those at risk of developing Type 2 diabetes. However, the high costs associated with CGMs remain a significant barrier for many potential users, especially those without health insurance. Despite the potential benefits, experts caution that the current research supporting the use of CGMs for non-diabetic individuals is limited. The devices are primarily designed for diabetes management, and their application in broader health contexts is still being explored. As the market for consumer health technology expands, companies like Abbott and Dexcom are poised to profit from this trend, even as the medical community continues to evaluate the implications of widespread glucose monitoring. In conclusion, while the availability of over-the-counter CGMs represents a significant advancement in personal health technology, it also raises questions about accessibility, affordability, and the need for further research into their effectiveness for non-diabetic users.